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Abstract 
Background: There are well-recognised gaps between evidence-based recommendations and 
prescribing practices in asthma. While different strategies have been devised to improve rational 
prescribing, the impact of these is uncertain.  
Aim: To examine the characteristics and effectiveness of strategies to improve rational prescribing in 
asthma.  
Method: We systematically searched electronic databases to find studies that reported on strategies 
to improve prescribing in asthma, or included rational prescribing as one of the main components of 
the program.  
Results: There were thirteen relevant studies. All of the strategies described in these studies 
involved physician education using a variety of modalities; two of the trials also included patient-
specific prescribing direction. Twelve of thirteen studies reported improved prescribing practice. 
There was significant heterogeneity in the interventions and outcome criteria employed by the 
studies. 
Conclusion: Strategies to improve rational prescribing in asthma show promise, but the significant 
methodological heterogeneity, and the absence in most cases of demonstrable clinical benefit, raise 
concerns about their applicability in clinical practice.  
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Introduction 
The World Health Organization’s Guide to Good Prescribing outlines the steps involved in rational 
medicines use: defining the clinical problem and therapeutic aims, assessing efficacy and safety, 
commencing treatment, providing instructions, including about potential adverse effects, and 
monitoring treatment.1 The Quality use of Medicines (QUM) framework adopted in Australia is a 
broader concept that considers the patient, doctor, other health professionals and policy factors 
that impact on medicine use. The Quality Use of Medicines framework has established rational 
prescribing as a national health priority, and a key strategy to improving the quality and cost-
effectiveness of healthcare in Australia.2 However there are numerous barriers to rational 
prescribing in clinical practice, including: commitment to established therapies, scepticism towards, 
and ignorance of, novel drugs, and limited resources available for non-commercially sponsored 
education about evidence based treatments.3,4 The management of asthma, one of the most 
commonly encountered chronic diseases in primary care, may be used as an exemplar of the issues 
raised by efforts to improve rational prescribing. 
The key aim in management of asthma is to decrease airway inflammation and achieve disease 
control: this requires the judicious use of ‘preventer’ medications if necessary (most commonly 
inhaled corticosteroids), and not simply acute treatment of symptoms with short acting 
bronchodilators.5 Step up therapies including long acting beta agonists or leukotriene receptor 
antagonists should be considered if there is insufficient disease control.6 Unfortunately, there 
remains a gap between the recommendations of evidence based guidelines and documented 
prescribing practices for asthma in primary care. The Australian CareTrack study recently assessed 
the appropriateness of care for a number of common diseases, and found that asthma patients 
received care consistent with evidence based guidelines in only 38% of encounters.7 The reasons for 
this are unclear but, as Goeman and colleagues found in a report on a survey of Australian general 
practitioners, barriers to achieving optimal management of asthma may include time limitations, 
cost and poor access to education and training.8   
This gap has spurred the development of strategies to improve prescribing practices, including 
physician education programs via individual or group teaching from other clinicians and pharmacists, 
distance education and/or case conferences,  clinical audit, and feedback.9 A number of studies have 
examined the impact of these strategies on clinical practice and/or patient outcomes. This study 
provides a qualitative review of the evidence for the efficacy of strategies to improve rational 
prescribing in asthma.  
 
Methods 
Search strategy 
The search strategy aimed to capture all recent studies of programs to improve rational prescribing 
in asthma. We performed a search of the Medline, Embase and the Cochrane databases for studies 
published in English and dated from January 2004 to August 2014 using MeSH terms and keywords 
for titles and abstracts. Search terms related to asthma, airways disease, prescription, appropriate 
prescription, rational prescription, inhalers, bronchodilators, corticosteroids, reliever, preventer, 
management and clinical practice guidelines. The purposefully broad search allowed the capture of 
studies that did not use the term ‘rational prescribing’, but did study the concept. The abstracts 
were reviewed, and the references of included studies were reviewed for any additional relevant 
studies.  
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Study inclusion, selection and analysis 
This review focused on studies that examined strategies to improve rational prescribing for asthma. 
Studies of programs that did not specifically describe the effect of interventions on prescribing were 
excluded. 
Inclusion criteria: 
 Studies based in the primary care setting 
 Primary focus of at least one arm of intervention on prescribing of medications 
 Target population of children and/or adults 
Exclusion criteria: 
 Primarily hospital or emergency based programs 
 Primary focus of program not on prescribing (for example disease monitoring, inhaler 
technique, application of generic management guidelines) 
A quality assessment of all trials was completed using the Cochrane risk of bias tool for randomised 
and non-randomised trials as described by the Cochrane Effective Practice and Organisation of 
Care.10 The following criteria were considered: randomisation, allocation concealment, baseline 
outcomes and characteristics, treatment of incomplete data, blinding, contamination, and selective 
reporting. An overall rating of bias was given with grades low, moderate and high. Studies were 
analysed according to study design, population size, target population, location, strategy and 
outcome measures.  Studies with common methods and/or outcomes were grouped together to 
facilitate qualitative analysis. 
 
Results 
Study characteristics and quality assessment 
From the initial search 13 studies met the inclusion criteria, with the remainder excluded due to an 
insufficient focus on prescribing as the key component of the study intervention. However given the 
broad inclusion criteria, the studies did vary significantly in their methodology; study characteristics 
and the overall assessment of bias are summarised in Table 1. Eight of the thirteen studies were 
randomised controlled trials, involving the randomisation of either individual general practitioners or 
cluster randomisation primary care groups or sites. The remainder of the studies were prospective 
observational or cohort studies that tracked outcomes with time and compared outcomes to the 
control group or to historical outcomes.  
A quality assessment of the 13 included studies rated four studies at low, four at moderate and five 
at high risk of bias. Contributing factors to the risk of bias was inadequate or incomplete explanation 
of randomisation and blinding procedures. Issues of contamination were not addressed in most of 
the trials, including those studies utilising cluster randomisation. More generally there was 
inconsistent reporting of baseline characteristics and outcomes. The measurement of clinical 
outcomes was further complicated by the heterogeneity in the definition of rational prescribing: 
some studies defined this in terms of adherence to asthma management guidelines, while others 
more broadly described rational prescribing in terms of minimisation of the prescription of short 
acting bronchodilators and increase in preventer therapy (for example inhaled corticosteroids). 
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Study Study population Study type Intervention description Length of follow up Outcome measures Risk of bias 
Lee et 
al.
11
 
n=249 physicians 
n= 14292 children aged 5-18 
Prospective 
observational study 
Review of current patient 
medications and education material 
mailed to treating physician 
12 month follow up Drug utilisation, hospitalisations 
and emergency visits 
Program satisfaction 
High 
Davis et 
al.
 12
 
Primary care physicians (n=20 
intervention, n=34 control) 
Controlled study 3 teleconferences with interactive 
discussion of clinical cases 
6 month follow up  Prescribing practices  
Program satisfaction 
High 
Lozano et 
al.
 13
 
Paediatric primary care clinics 
(n=42), children aged 3-17 
(n=638) 
Randomised 
controlled trial 
Three groups: (A) usual care, (B) 
peer education, (C) peer education 
and nurse-mediated organisation 
change 
2 year study duration Asthma symptoms, health status, 
frequency of ‘bursts’ of oral 
steroids 
 Moderate 
Witt et 
al.
 14
 
Primary care physician 
practices (n=47 intervention,  
n=53 control) 
Cluster randomised 
controlled trial 
Education using locally developed 
guideline and prescribing data, 
either through personal education 
or via correspondence 
12 month follow up Prescribing practices, physician use 
of spirometry and peak flow 
Moderate 
Cloutier 
et al.
15
 
Primary care clinics (n=6), 
3748 children 
Cohort study Management program for 
assessment of asthma, clinical 
severity and prescribing  
4 years study 
duration 
Hospitalisation and emergency 
room admissions, prescribing 
practices 
Moderate 
Moonie 
et al.
16
 
Primary care clinics (n=2), 723 
patients aged 1-85 
Prospective 
observational study 
Standardised forms for assessment 
of symptoms and prescribing, 
personal education sessions 
12 month study 
duration  
Accuracy of physician assessment, 
prescribing practices (consistency 
with guidelines) 
High 
Mitchell 
et al.
17
 
Primary care physicians 
(n=270) 
Randomised 
controlled trial 
Education session based on care 
pathway 
24 month study 
duration 
Hospital and emergency room 
admissions 
Low 
Kattan et 
al.
 18
 
Primary care, children aged 5-
11 (n=466 intervention, n=463 
usual care) 
Randomised 
controlled trial 
Assessment of patient symptoms 
and brief guidance to physicians 
based on national guidelines 
12 month follow up Asthma symptoms, 
hospitalisations, ED visits, 
physician visits, prescribing 
practices 
Low 
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Above: Table 1. Characteristics of those studies included in the review 
Hagmole
n of ten 
Have
 
et 
al.
 19
 
Primary care, children aged 7-
17 (n=404)  
Randomised 
controlled trial 
Three groups: (A) guideline 
dissemination (B) guideline 
dissemination and education, (C) 
guideline dissemination, education 
and treatment advice 
12 month follow up Airway hyperresponsiveness 
(primary), asthma symptoms, peak 
flow, prescribing practices 
(secondary) 
Moderate 
Cho et 
al.
20
  
 
Primary care (n=377 
physicians, n=4682 patients) 
Prospective 
observational study 
Computer assisted program on 
management 
3 month follow up Symptom scores, prescribing 
practices 
High 
de Vries 
et al.
 21
 
Primary care, children aged 0-
14 (n=1447 intervention,  
n=3527 reference group) 
Prospective 
observational study 
Pharmacist education of primary 
care physicians based on guidelines 
unclear Prescribing practices High 
Bell et 
al.
22
 
Primary care practices (n=12), 
children aged 2-18  
Cluster randomised 
trial 
Clinical decision support embedded 
in electronic health record 
24 months follow up Controller medication prescription, 
asthma plan, spirometry 
Low 
Shah et 
al.
 23
 
Primary care practitioners 
(n=66 intervention, n=56 
usual care), children aged 2-
14 
Randomised 
controlled trial 
Small group physician led 
interactive workshop   
12 month follow up Asthma symptoms, prescribing 
practices, GP feedback, asthma 
action plan 
Low 
 
 
6 | P a g e  
 
Impact of strategies to improve prescribing 
Twelve of thirteen studies in this review reported strategies that were successful in improving 
rational prescribing in asthma: a description of the interventions and the outcomes are summarised 
in Table 2. Most of the studies evaluated physician educational programs including provision of 
written educational materials and interactive case-based teleconferences with content experts. Each 
study utilised a different definition of rational prescribing depending on the clinical context and 
study aims: in general they aimed for increased use of inhaled corticosteroids (ICS), minimisation of 
short acting bronchodilators (SABAs), and had varying approaches to long acting bronchodilators 
(LABAs), reflecting the ongoing debate about the place of LABAs in asthma management.24,25 Table 2 
indicates whether results were positive based on each study’s respective outcome measures.    
Davis et al. delivered education to physicians using interactive case based discussions, and 
demonstrated an increase in prescription of inhaled corticosteroids (ICS) from 2.54 per month to 
7.76 per month (p<0.001).12 Shah et al. found that their education program decreased the rate of ICS 
prescribing in patients with infrequent symptoms, but did not change any clinical outcomes.23 de 
Vries et al. described a pharmacist led education program that increased the number of children 
with short acting bronchodilator (SABA) prescriptions (p<0.01), and decreased the number of 
children on long acting bronchodilators (LABA)  with no prescribed ICS (p=0.03).21 Mitchell et al. used 
education sessions to outline validated clinical pathways, with a subsequent decrease in oral reliever 
medications (48.4% in intervention group, 28.6% in control, p<0.001), and reduction in 
hospitalisation. 17In the only study to find no impact on prescribing practice, Witt et al. found that 
guideline based education delivered personally or via correspondence did not change prescribing 
rates of SABAs or ICS.14  
Some of the studies examined more multifaceted interventions. Lozano et al. compared usual care 
with peer leader education, and with peer leader education combined with nurse driven 
organisational change: the latter two groups both had reduced prescribing of short course steroids, 
and had 6.5 and 13.3 fewer asthma symptom days over 2 years respectively (p=0.02).13 A Dutch 
group compared three interventions: guideline dissemination (A), guideline dissemination and 
education (B), guideline dissemination, education and treatment advice (C). Although there was an 
increase in use of ICS in group C (0.4 puffs/day compared to 0.3 puffs/day for groups A and B), there 
was no difference in the primary clinical endpoint of airway hyper-responsiveness between the 
groups.19 Cloutier et al. studied an adaptive set of guidelines individualised for patients, that resulted 
in increased appropriate controller medication use and a 35% decrease in hospitalisation 
(p<0.006).15 
Some programs extended beyond education to specific advice about the management of individual 
patients. Kattan et al. described a program where clinical information, including medications use, 
was collected from patients and their families, and then provided to their primary care physician in 
conjunction with recommendations for medication changes.18 This resulted in a significant increase 
in appropriate stepping up of asthma therapy (46% of visits) compared to a control group (35.6% of 
visits). Lee et al. studied the impact of providing a review of individual patient medications in 
addition to educational material: although there was a drop in SABA use from 300 to 200 puffs per 
month, there was no change in clinical outcomes as measured by emergency visits and asthma 
related hospitalisation.11 
Technology can facilitate the individualisation of prescribing advice, as education can be integrated 
with electronic health records. Cho et al. described such as program that reduced the use of SABAs 
and systemic steroids and increased preventer medication use. 20 Bell et al. also reported on an 
integrated electronic program with success in urban paediatric practices, increasing the use of 
preventer medications.22 
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Above: Table 2. Summary of results of reviewed studies 
Study Prescribing practices Clinical outcomes Physician outcomes 
Lee et al.
11
 Decrease in SABA use from 300 to 200 puffs per month and 
change in LABA utilisation in 83% of participants 
[discontinuation of LABA or addition of SABA] 
(positive change) 
No change in emergency visits or asthma related 
hospitalisation 
56% modified their drug therapy 
70% intend to use “Asthma diary” in 
their practice 
Davis et al.
 12
 Increase in prescription of ICS from 2.54 per month to 7.76 per 
month (p<0.001) (positive change) 
No change in SABA use (negative change) 
No measurement of clinical outcomes 80% believed program changed 
prescribing practices 
Lozano et al.
 13
 Peer leader group: 36% reduction in oral steroid bursts 
Planned care group: 39% reduction in oral steroid bursts 
(positive change) 
Peer leader group: 6.5 fewer asthma symptom 
days  (non -significant reduction) 
Planned care group: 13.3 fewer asthma symptom 
days (p=0.02) 
No physician outcomes reported 
Witt et al.
 14
 No difference between control and intervention groups in 
prescribing of SABA and ICS (negative change) 
No specific clinical outcome measures reported No dropout of physicians from 
intervention group 
Moonie et al.
15
 Appropriate prescribing (as per NAEPP guidelines) improved 
with time from 69% at first visit to 91% at visit 4 (p=0.02) 
(positive change) 
No specific clinical outcome measures reported No physician outcomes reported 
Kattan et al.
 16
 46% of visits resulted in appropriate step up of therapy (as per 
NAEPP guidelines) compared to 35.6% in control group (p=0.03) 
(positive change) 
Intervention: fewer emergency visits (0.83/year 
compared to 1.14/year for control, p=0.013), no 
significant difference in hospitalisation, 
symptoms days or school missed  
No physician outcomes reported 
Have
 
et al.
 17
 Increase in use of ICS in group C (0.4 puffs/day compared to 0.3 
puffs/day for groups A and B, p<0.05) (positive change) 
No change is use of SABA use (negative change) 
No difference between groups in airway 
hyperresponsiveness (p=0.09), improvement in 
nocturnal symptoms groups A and C 
No physician outcomes reported 
de Vries et al.
 18
 Increase number of children with SABA prescriptions (p<0.01), 
fewer children on LABA  with no ICS (p=0.03) (positive change) 
No specific clinical outcome measures reported No physician outcomes reported 
Shah et al.
 19
 Patients with infrequent symptoms had lower ICS and LABA use 
(p=0.02) (positive change) 
No statistically significant difference in child days 
away from school or parent days away from 
work 
General practitioners more confident 
communicating with patients (p=0.03)  
SABA = short acting bronchodilators, LABA = long acting bronchodilators, ICS = inhaled corticosteroids, NAEPP = national asthma education and prevention program. 
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Discussion 
This review suggests that strategies (most of which involve physician education) have the capacity to 
improve the rate of rational prescribing in asthma, with eight of nine studies demonstrating 
improvement in at least one prescribing parameter.  Despite this, the heterogeneity of these studies, 
concerns about study quality, and limitations in the methodology such as single time-point analysis 
of outcomes and use of surrogate outcomes, limits our capacity to draw generalisable conclusions or 
to make any judgment regarding the most effective strategy to improve the quality of prescribing.  
Insofar as patient outcomes were measured, there was great variability in the definition of clinical 
endpoints such as symptom control, exacerbations, and quality of life, and no study consistently 
followed The American Thoracic Society and European Respiratory Society recommended outcome 
measures for assessing treatment effects.26 Furthermore the practical applicability of the programs 
was not addressed by all the studies, with only a minority reporting on physician satisfaction and 
willingness to adopt the strategies in their routine clinical practice.  
It may be unrealistic to hold these small studies of interventions to improve prescribing to the 
standard of clinical trials of new therapies; however our findings do demonstrate the need for more 
consistent and rigorous studies of interventions to improve prescribing practice. In particular, we 
need a more consistent definition of rational prescribing, both in general and in relation to asthma. 
We also need more consistent adherence to standards for assessing effects of interventions. 
Without this, efforts to improve the “quality use of medicines” will continue to struggle. 
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